Study on Tislelizumab with New Treatments for Non-Small Cell Lung Cancer

Sponsor: BeiGene

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT05635708

Provider View

This clinical trial is testing the effectiveness and safety of the drug Tislelizumab, combined with other new treatments, for patients with non-small cell lung cancer (NSCLC). The study is divided into two parts based on the level of a specific protein (PD-L1) in the cancer cells.

Patient Parameters

Program Overview

The aim of this study is to evaluate how well Tislelizumab, when used with other investigational drugs, works against non-small cell lung cancer (NSCLC). The study also looks at the safety and tolerability of these treatments, with or without chemotherapy. It is organized into two sub-studies: one for patients whose cancer cells have high levels of the PD-L1 protein (50% or more) and another for those with low or no PD-L1 protein (less than 50%).

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that is either locally advanced, has come back, or has spread to other parts of the body, and cannot be treated with surgery or radiation.
  • Have not received any previous systemic treatment for metastatic NSCLC. Previous chemotherapy or radiation for locally advanced cancer is allowed if it was completed at least 6 months before joining the study.
  • Have a tumor that can be tested for PD-L1 protein levels, either from a previous sample or a new biopsy. Patients must know their PD-L1 status to participate.
  • Have at least one tumor that can be measured using standard criteria.
  • Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

  • Have a type of lung cancer that includes small cell lung cancer.
  • Have known genetic mutations in the cancer that can be treated with specific targeted therapies.
  • Have previously received treatments that target PD-1, PD-L1, or other similar immune pathways, unless it was part of a previous treatment completed more than 6 months ago.
  • Have used Chinese herbal or patent medicines for cancer control within 14 days before joining the study.
  • Have active cancer spread to the brain or spinal fluid, or have uncontrolled autoimmune diseases.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.